



CODEN [USA]: IAJPB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<https://zenodo.org/records/13085543>Available online at: <http://www.iajps.com>

Research Article

**PREPARATION AND EVALUATION OF PULSATILE DRUG
DELIVERY OF TRAMADOL HYDROCHLORIDE****J.Mahendra Prasad*¹, M. Ramya Teja ² and J. N. Suresh Kumar³**¹Research Scholar, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Palnadu(Dt), Andhra Pradesh, pin:522601.²Associate Professor, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Palnadu(Dt), Andhra Pradesh, pin:522601.³Principal, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Palnadu(Dt), Andhra Pradesh, pin:522601**Abstract:**

In the present study, an effort was made to develop the pulsatile drug delivery of Tramadol hydrochloride to the colon. A time delayed capsule was prepared by sealing the microspheres inside the insoluble hard gelatin capsule body with erodible hydrogel plug. The microspheres were prepared by emulsion solvent evaporation technique... Optimized microsphere formulations were selected based on dissolution studies. The entire device was enteric coated, so that the variability in gastric emptying time can be overcome and a colon-specific release can be achieved. Hydrogel plug (HPMCK100 and lactose in 1:1 ratio) having 4.5kg/cm² hardness and 100 mg weight was placed in the capsule opening and found that it was satisfactory to retard the drug release in small intestinal fluid and to eject out the plug in colonic fluid and releasing the microspheres into colonic fluid after a lag time criterion of 5 hours. In order to simulate the pH changes along the GI tract, three dissolution media with pH 1.2, 7.4 and 6.8 were sequentially used. FTIR study confirmed that there was no interaction between drug and polymer. Among all the formulations Tramadol hydrochloride microspheres prepared with Eudragit RL 100 in 1:2 ratio shown prolonged release for a period of 12 hours. The obtained results revealed the capability of the system in delaying drug release for a programmable period of time and can prevent a sharp increase in the blood pressure during the early morning hours, a time when the risk of hypertension is the greatest.

Keywords: Metoprolol succinate; Hypertension; Pulsatile; Microspheres; Hydrogel Plug; Solvent evaporation**Corresponding author:**

J.Mahendra Prasad,
Research Scholar,
Department of Pharmaceutics,
Narasaraopeta Institute of Pharmaceutical Sciences,
Narasaraopet, Palnadu(Dt), Andhra Pradesh, pin:522601

QR code



Please cite this article in press J.Mahendra Prasad et al., **Preparation And Evaluation Of Pulsatile Drug Delivery Of Tramadol Hydrochloride**, Indo Am. J. P. Sci, 2024; 11 (07).

INTRODUCTION:

Pulsatile systems are designed in a manner that the drug is available at the site of action at the right time in the right amount. These systems are beneficial for drugs having high first-pass effect; drugs administered for diseases that follow chronopharmacological behavior, drugs having specific absorption site in GIT, targeting to colon, and cases where night time dosing is required¹. Rheumatoid arthritis is a chronic inflammatory autoimmune disorder. The cardinal signs of rheumatoid arthritis are stiffness, swelling and pain of one or more joints of the body characteristically most severe in the morning. Rheumatoid arthritis shows a marked circadian variation in its symptoms. Ratings of the severity of joint pain swelling and stiffness were about 3 times higher between 08:00 and 11:00 am than at bedtime.³ Tramadol hydrochloride is a synthetic analgesic with half life of 5-6 hrs and has a modest affinity for the μ receptor. Its additional effect on the descending inhibitory pathways relies on inhibition of serotonin and norepinephrine re-uptake. The dose of tramadol is 50-100mg daily by oral route in divided doses. Thus it gives dual mode of analgesic action. It doesn't only provide analgesia over a wide range of pathologies but it has significant advantages like no respiratory depression or cardiac side effects. It is BCS class-I drug having good absorption throughout the GIT. The most common side effects of Tramadol HCl are nausea and vomiting which can be prevented by pulsatile delivery.

The pulsatile drug delivery of Tramadol hydrochloride can be taken before bed time (10 pm) and capable of releasing drug at 3.00 am by proportioning drug concentration in the early morning hours when risk of symptoms of rheumatoid arthritis is the greatest⁵. The intentionally delaying the drug absorption for a specified time period of 5 hours (lag time) was controlled by hydrogel plug which will be taken at bed time with a programmed start of drug release early in morning hours.

MATERIALS AND METHODS:

Tramadol hydrochloride was a gratis sample obtained from Ranbaxy Lab. Ltd. (India). Eudragit RL 100, Eudragit RLPO, were obtained from Himedia; Mumbai. HPMC K100, HPMC K4, HPMC K15 and HPMC 50cps were purchased from SD fine chemicals, Mumbai. All reagents used were of analytical-reagent grade.

Preparation of Cross-Linked Gelatin Capsules:

Approximately 100 number size 0 hard gelatine capsules were taken. Bodies were separated from cap,

25 ml of 15% (v/v) formaldehyde was taken into desiccators and a pinch of potassium permanganate was added to it, to generate formalin vapours. The wire mesh containing the empty bodies of capsule was then exposed to formaldehyde vapours. The caps were not exposed leaving them water-soluble. The desiccators were tightly closed. The reaction was carried out for 12 h after which the bodies were removed and dried at 50°C for 30 min to ensure completion of reaction between gelatine and formaldehyde vapours. The bodies were then dried at room temperature to facilitate removal of residual formaldehyde⁶. These capsule bodies were capped with untreated caps and stored in a polythene bag.

Preparation of Hydrogel Plug:

Plug for sealing the capsule body was prepared by compressing equal amount of equal amount of HPMC K100: lactose, c HPMC K4: lactose, HPMC K15: lactose, and HPMC 50cps : lactose using 7 mm punches and dies on rotary tablet press keeping varying thickness and hardness values of tablet plug⁷.

Preparation of microspheres:

All the microspheres formulations were prepared by emulsion solvent evaporation technique⁸ and the composition was shown in table 1. The effect of various formulation and processing factors on microspheres characteristics were investigated by changing polymer: drug ratio. Weighed amount of Tramadol hydrochloride and polymer in 1:1 ratio were dissolved in 10ml of chloroform. The homogeneous drug and polymer organic solution was then slowly added in a thin stream to 100ml of liquid paraffin containing 1% surfactant (span 80) with constant stirring for 1h. The resulting microspheres were separated by filtration and washed with petroleum ether. The microspheres finally air dried over a period of 12 hrs and stored in a desiccator. In case of 1:1.5 and 1:2 core:coat ratios, the corresponding polymer get varied respectively.

Designing of Pulsincap:

The Pulsincap was designed by filling the microspheres equivalent to 50 mg of Tramadol hydrochloride into the formaldehyde treated bodies by hand filling. The capsules containing the microspheres were then plugged with optimized hydrogel plug. The joint of the capsule body and cap was sealed with a small amount of the 5% ethyl cellulose ethanolic solution⁹. The sealed capsules were completely coated by dip coating method with 5% cellulose acetate phthalate in 5:5 (v/v) mixture of acetone: ethanol plasticized with n-dibutylphthalate (0.75%), to prevent variable gastric emptying. Coating was repeated until

an 8–12% increase in weight is obtained. % weight gain of the capsules before and after coating was determined ¹⁰.

Physicochemical Characterization of Hydrogel Plug

Hydrogel Plugs were studied for hardness, friability, weight variation and lag time ¹⁰.

Drug content uniformity:

Then encapsulated microspheres equivalent to 50mg of Tramadol hydrochloride were taken into mortar and grounded with the help of pestle. The grounded power mixture was dissolved in 6.8 pH buffer, filtered and estimated spectrophotometrically at 224 nm¹¹.

***In vitro* release profile of pulsatile capsule:**

Drug release studies of pulsincaps were carried out using a USP XXIII dissolution rate test apparatus (Apparatus 2, 100 rpm, 37 °C) for 2 hr in 0.1 M HCl (900 ml) as the average gastric emptying time is about 2 hr. Then the dissolution medium was replaced with pH-7.4 phosphate buffer (900 ml) for 3hr as the average small intestinal transit time is about 3 hr. After 5 hr, the dissolution medium was replaced with pH 6.8 phosphate buffer (900 ml) and tested for subsequent hours. Nine hundred milliliters of the dissolution medium was used at each time. Rotation speed was 100 rpm and temperature was maintained at 37±0.5°C. Five milliliters of dissolution media was withdrawn at predetermined time intervals and fresh dissolution media was replaced. The withdrawn samples were analyzed at 224 nm, by UV absorption spectroscopy and the cumulative percentage release was calculated over the sampling times ¹².

IR spectral studies:

The IR Spectra for the formulation, pure drugs and excipients were recorded on JASCO FT-Infra Red Spectrophotometer using KBr pellet technique¹³ at the resolution rate of 4 cm⁻¹. Spectrum was integrated in transmittance mode at the wave number range 380 to 4368 cm⁻¹.

RESULTS AND DISCUSSION:

Pulsincap dosage form was a capsule which consists of a water insoluble body and a water-soluble cap. The microspheres were sealed within the capsule body by means of a hydrogel plug. When the pulsing cap was swallowed, the water soluble cap dissolves in the gastric juice and the exposed hydrogel plug begins to swell. At predetermined time after ingestion, the swollen plug was ejected out and the encapsulated drug formulation was then released into the colon, where it is dissolved and then absorbed into blood

stream. In the present study, capsule bodies which were hardened with formaldehyde treatment for 12 hrs were used for the preparation of pulsincaps. It was sealed with unhardened cap of the capsule. The microspheres were prepared by emulsion solvent evaporation technique. The method employed gave discrete, spherical, non-sticky and free flowing microspheres. As aggregates these microspheres were also non-sticky and free flowing. The formation of a stable emulsion in the early stages is important if discrete microspheres are to be isolated. An optimal concentration of emulsifier is required to produce the finest stable dispersion. Below optimal concentration the dispersed globules/droplets tend to fuse and produce larger globules because of insufficient lowering in interfacial tension, while above the optimal concentration no significant decrease in particle size is observed, because a high amount of emulsifying agent increases the viscosity of the dispersion medium. The optimal concentration of surfactant was found to be 1.0%. Microscopic examination of the formulations revealed that the microspheres were spherical and appeared as aggregates or discrete particles.

All the formulations offered good flow properties. The particle size of the microspheres ranged between 613.23 and 662.53 μm. The use of the surfactant permits the remarkable reduction in the size of the microspheres as the result of decrease in the interfacial tension. All formulations had a narrow particle size distribution. The mean particle size of microspheres was influenced by the type of polymer proportion in the formulation. The mean size increased with increasing polymer concentration. Increasing polymer concentration produced a significant increase in viscosity of the internal phase, thus leading to an increase of emulsion droplet size and finally a higher microspheres size. Microspheres were developed with 1:1, 1:1.5, 1:2, ratios of core : coat to determine the effect of coating material concentration on the release rate of Metaprolol succinate. These microspheres were characterized for Drug Content and % Encapsulation Efficiency. The results are given in Table 2. The technique also showed good entrapment efficiency. Hydrogel Plugs were evaluated for hardness, friability, weight variation and lag time and the results were shown in Table 3. The formulations fitted with the various hydrogel plugs HP1, HP2, HP3, HP4 shown 0.2%, 6.18%, 16.37% and 18.34% of drug release respectively at the end of 5th hour. It was observed that 100 mg hydrogel plug (HPMC K100: lactose in 1:1 ratio) having 4.5 kg/cm² hardness was satisfactory to retard the drug release in small intestinal fluid and to eject out the plug in colonic fluid and releasing the microspheres into colonic fluid. This suggested that

the lag time could also be adjusted and influenced by the plug composition.

During dissolution studies, it was observed that, the enteric coat of the cellulose acetate phthalate was intact for 2 hrs in pH 1.2, but dissolved in intestinal pH, leaving the soluble cap of capsule, which also dissolved in pH 7.4, then the exposed polymer plug absorbed the surrounding fluid, swelled and released the drug through the swollen microspheres. After complete wetting of the plug, it formed a soft mass, which was then easily ejected out of the capsule body; releasing the microspheres into simulated colonic fluid (pH 6.8 phosphate buffer). From the *In-vitro* release studies of device, it was observed that with all formulation, there was absolutely no drug release in simulated gastric fluid (acidic pH 1.2) for 2 hours and in simulated intestinal fluid (pH 7.4 phosphate buffer). Continuous release was found in colonic medium (pH 6.8 phosphate buffer).

In-vitro release profiles in colonic medium were found to have very good sustaining efficacy. Pulsin caps loaded with Tramadol hydrochloride microspheres prepared with Eudragit RL 100 in 1:1,1:1.5 and 1:2 ratios shown sustained drug release for a period of 10 hours (5th hour to 15th hour), 11 hours (5th hour to 16th hour) and 12 hours (5th hour to 17 hour) respectively. respectively and are shown in figure 1. Pulsin caps loaded with Tramadol hydrochloride microspheres prepared with ethyl cellulose in 1:1,1:1.5 and 1:2 ratios shown sustained drug release for a period of 9.5 hours (5th hour to 14.5th hour), 10.5 hours (5th hour to 15.5th hour) and 11.5 hours (5th hour to 16.5 hour) respectively and are shown in figure 2.

The correlation coefficient values for dissolution kinetics data was shown in the Table 4. These values clearly indicated that the drug release followed zero order kinetics and the mechanism of drug release was governed by peppas - korsmeyer model. The exponential coefficient(n) values were found to be in between 0.7903 to 0.8573 indicating non fickian diffusion mechanisam.

The FTIR spectrum of Tramadol hydrochloride pure drug (Figure 3) showed characteristic peaks at wave numbers were C-O Str – 1095.58 cm⁻¹, C-O Str in C-O-C – 1189.01 cm⁻¹, C-O Str in C=C-O-C – 1280.66 cm⁻¹, C=C Ring Str – 1571.95 cm⁻¹, N-C Str – 3174.66 cm⁻¹ denoting stretching vibration. The FTIR spectrum(Figure 4) of optimized formulation (F4) showed more or less similar peaks in all drug loaded microspheres. There were no change or shifting of the characteristic peaks in drug and excipient mixtures suggested that there was no significant drug polymer

interaction which indicates the stable nature of the drug in all formulations. From the figures it was observed that similar peaks were also reported in optimized formulation. There was no change or shifting of characteristic peaks in drug loaded microspheres suggested that there was no significant drug polymer interaction which indicates the stable nature of the drug in optimized formulation.

CONCLUSION:

Among all the formulations Pulsin caps loaded with Tramadol hydrochloride microspheres prepared with Eudragit RL 100 in 1:2 ratio shown prolonged release for a period of 12 hours. The obtained results showed the capability of the system in delaying drug release for a programmable period of time and the possibility of exploiting such delay to attain colon targeting. In accordance with the chronomodulated therapy of hypertension, the lag time criterion of 5 hours and sustained release for a period of 12 hours was satisfied. The dosage form can be taken at bed time and will release the contents in the early morning hours when the pain is more prevalent.

REFERENCES:

1. Asija Rajesh, Patel Jaimin, Asija Sangeeta, A novel approach: pulsatile drug delivery system, Int Res J of Pharmacy, 3(9), 2012 , 43-49.
2. Nagaraju. R, Sai meera. D. Core – In – Cup Tablet Design of Metoprolol succinate and its Evaluation for controlled release. Current Drug Discovery Technologies 2009; 6: 299 – 305.
3. Basu VR, Balagani PK. Design and Characterization of Pulsatile Drug Delivery System for Metoprolol Succinate. J Compr Phar 2014;1(5):168-175.
4. Rose marie,R and Dadiv,R. Drugs used for the treatment of myocardial ischemia.In,Joel,G H(ed),Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th edition. New York, McGraw-Hill medical Publishing Division, 2005; 1786-1787.
5. Halsas M, Ervasti P, Veski P, Jürjenson H, Marvola M. Biopharmaceutical evaluation of timecontrolled press-coated tablets containing polymers to adjust drug release. Eur J Drug Metabol Pharmacokinet., 23,1998, 190-196 .
6. Kro gel, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug, Pharm. Res.,15 (3) ,1998, 474-481.
7. Sandeep M, Sai Kishore V, Sudheer B, Ershad S, Adithya K, Phanil kumar DS, Design and development of chronopharmaceutical drug delivery of lansoprazole Asian Journal of Pharmaceutical Research and Development , 1(5) ,2013,1-9.

8. Ramesh B , Saikishore V, Lakshmana Rao R. Design And Development Of Pulsincap For Chronopharmaceutical Drug Delivery Losartan Potassium . Asian Journal of Pharmaceutical Research and Development. 2014,,2(3) ,78-86.
9. Dasharath M Patel, Rushiraj H Jani, Chhagan N Patel. Design and evaluation of colon targeted modified pulsincap delivery of 5-fluorouracil according to circadian rhythm, Int J Pharm Investig , 1(3),2011,172–181.
10. Geest S, Koker J, Demeester J, De Smedt S, Hennink WE. Pulsed in vitro release and in vivo behavior of exploding microcapsules. J. Control. Release., 135, 2009,268-73.
11. Kumar S, Nagpal K, Singh SK, Mishra DN. Improved bioavailability through floating microspheres of lovastatin. Daru., 19(1),2011,57–64.
12. Kaur Dupinder , Saini Seema. Development and characterization of lovastatin loaded microspheres. Int. Res J Pharm. App Sci., 3(5), 2013 , 197-205.
13. Yamada.T, Onishi H, Machida Y, Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylcellulose Journal of Controlled Release., 75, 2001, 271–282.
14. Sarfaraz Md , Venubabu. P, Hiremath Doddappa., Prakash S.G. Mucoadhesive Dosage Form Of Glibenclamide: Design And Characterisation. Int J Pharm and Biological Sci ,2(2), 2012 ,162-172.
15. Saraf S, Dashora K, Effect of processing variables on microparticulate system of aceclofenac. Pak. J. Pharm. Sci., 19 (1), 2006, 1-6.

Table.1: Preparation of Tramadol hydrochloride microspheres

Polymer employed			
Eudragit RL 100		Eudragit RL PO	
Formulation Code	Core: Coat	Formulation Code	Core: Coat
F-1	1:1	F-4	1:1
F-2	1:1.5	F-5	1:1.5
F-3	1:2	F-6	1:2

Table 2: Table 6.14 : Flow properties of Tramadol Hydrochloride Microspheres

Formulation	Evaluation parameters				
	Bulk density (g/ml)	Tapped density (g/ml)	Compressibility index (%)	Hausner's Ratio	Angle of Repose (θ)
F ₁	0.426	0.502	15.13	1.17	23.24
F ₂	0.452	0.543	16.75	1.20	27.46
F ₃	0.469	0.571	17.86	1.19	28.12
F ₄	0.53	0.63	15.07	1.17	29.26
F ₅	0.54	0.62	12.82	1.14	29.37
F ₆	0.51	0.61	15.08	1.17	26.23

Table 3: Particle size , Drug content, Entrapment Efficiency,Wall thickness of Tramadol Hydrochloride Microspheres

Formulation	Coat:core Ratio	Mean diameter (µm)	% drug Content	Entrapment Efficiency	Wall thickness (µ m)
F ₁	1:1	360.48	49.39	98.78	28.68
F ₂	1:1.5	483.96	65.68	99.46	39.58
F ₃	1:2	602.72	74.75	99.29	46.70
F ₄	1:1	340.48	49.24	98.48	28.52
F ₅	1:1.5	463.99	65.58	99.33	39.44
F ₆	1:2	584.64	74.69	99.58	46.57

Table: 3 Evaluation characteristics of hydrogel plugs prepared with various natural polymers

Hydrogel Plug Code	Composition (1:1)	Weight (mg)	Thickness (mm)	Hardness (kg/cm ²)	Lag time (hours)
HP1	HPMC K 100 : Lactose	100±1.4	3.12	4.8	5
HP2	HPMC K 4 : Lactose	100±1.1	3.16	4.3	4.5
HP3	HPMC K15: Lactose	100±1.5	3.14	3.7	4
HP4	HPMC 50 cps: Lactose	100±1.2	3.24	3.4	3

Table: 4 In-vitro dissolution kinetics parameters of Tramadol hydrochloride microspheres

Formulation	Correlation coefficient				Release kinetics			Diffusion Exponent value(n)
	Zero order	First order	Higuchi	Peppas	K _o (mg/hr)	T ₅₀ (hr)	T ₉₀ (hr)	
F1	0.9894	0.8304	10.16	4.92	8.85	0.8147	0.9894	0.8304
F2	0.9910	0.8573	9.44	5.29	9.53	0.8206	0.9910	0.8573
F3	0.9939	0.8190	8.27	6.05	10.88	0.9188	0.9939	0.8190
F4	0.9916	0.8094	12.41	4.02	7.25	0.8565	0.9916	0.8094
F5	0.9943	0.7903	11.07	4.51	8.13	0.7664	0.9943	0.7903
F6	0.9957	0.7956	9.08	5.51	9.91	0.7862	0.9957	0.7956

Figure 1: Comparative *In-vitro* drug release profiles plot of Tramadol hydrochloride microspheres prepared with Eudragit RL 100 in different ratios




Figure 2: Comparative *In-vitro* drug release profiles plot of Tramadol hydrochloride microspheres prepared with ethyl cellulose in different ratios




Figure 3: FTIR spectrum of pure Tramadol hydrochloride




Figure 4: FTIR spectrum of optimized formulation

